<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">9675532</PMID>
      <DateCompleted>
        <Year>1998</Year>
        <Month>09</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0011-4162</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>62</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1998</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cutis</Title>
          <ISOAbbreviation>Cutis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Felodipine-induced gingival hyperplasia.</ArticleTitle>
        <Pagination>
          <StartPage>41</StartPage>
          <EndPage>43</EndPage>
          <MedlinePgn>41-3</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Felodipine is a calcium channel blocking agent used in the management of hypertension and angina. We report a case of gingival hyperplasia in a patient with chronic use of this drug. Gingival changes occurred soon after initiation of felodipine and improved upon its discontinuation. The clinical characteristics, inciting agents, proposed pathogenetic mechanisms, as well as prevention and treatment of drug-induced gingival hyperplasia are briefly reviewed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Young</LastName>
            <ForeName>P C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Service, Walter Reed Army Medical Center, Washington, DC., USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Turiansky</LastName>
            <ForeName>G W</ForeName>
            <Initials>GW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sau</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liebman</LastName>
            <ForeName>M D</ForeName>
            <Initials>MD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benson</LastName>
            <ForeName>P M</ForeName>
            <Initials>PM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cutis</MedlineTA>
        <NlmUniqueID>0006440</NlmUniqueID>
        <ISSNLinking>0011-4162</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005885" MajorTopicYN="N">Gingival Hyperplasia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1998</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1998</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1998</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">9675532</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
